Assessment of Diagnostic Performance and Role of Ga-68 PSMA-11 PET/CT in Patients with Advanced Hepatocellular Carcinoma

Asan Medical Center0 个研究点目标入组 50 人开始时间: 待定最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Patients who are older than19 years and capable of providing signatures in consent forms
•- Patients diagnosed with or suspected primary hepatocellular carcinoma by clinical information (blood test AFP, PIVKA elevation, etc.), imaging or pathology.
•- Patients with BCLC stage B or higher grade
•- Patients who have performed or are scheduled to perform tri-phase abdominal pelvic CT within a four-week period before Ga-68 PSMA-11 PET/CT and a two-week period after Ga-68 PSMA PET/CT after study enrollment
•- Patients who are willing to make a follow-up observation in our hospital for at least 6 months after study enrollment

•- If other primary cancers other than liver cancer were previously diagnosed or occurred at the same time
•- Patients within 3 weeks after chemotherapy or within 4 weeks after hepatic artery chemoembolization
•- Patients are under severe and/or uncontrolled and/or unstable medical conditions (e.g., congestive heart failure, acute myocardial infarction, degenerative brain disease, severe lung disease, etc.)
•- Patients who cannot stably perform CT or PET/CT imaging tests due to claustrophobia, dyskinesia, anxiety disorders, and etc
•- Where it is determined that the patient will not be eligible to completely collect data for clinical trials due to personal circumstances or other reasons

发起方